Print this page

Consolidated Statement of Comprehensive Income 

XLS

 

 

 

 

 

€ million

Q3 – 2014

Q3 – 2013

Jan.–Sept. 2014

Jan.–Sept. 2013

Profit after tax

249.6

342.5

883.0

927.6

Items of other comprehensive income that will not be reclassified to profit or loss in subsequent periods:

 

 

 

 

Remeasurement of the net defined benefit liability

 

 

 

 

Changes in remeasurement

–171.3

25.2

–416.5

–18.3

Deferred taxes

27.3

–4.0

72.4

2.7

Changes recognized in equity

–144.0

21.2

–344.1

–15.6

 

–144.0

21.2

–344.1

–15.6

Items of other comprehensive income that may be reclassified to profit or loss in subsequent periods:

 

 

 

 

Available-for-sale financial assets

 

 

 

 

Fair value adjustments

–1.1

0.8

–2.2

1.6

Reclassification to profit or loss

1.7

Deferred taxes

–0.1

–0.1

–0.6

Changes recognized in equity

–1.1

0.7

–0.6

1.0

Derivative financial instruments

 

 

 

 

Fair value adjustments

144.8

37.6

92.3

81.3

Reclassification to profit or loss

–9.0

–8.2

–35.3

–13.1

Reclassification to assets

Deferred taxes

–17.6

–8.8

1.5

–16.0

Changes recognized in equity

118.2

20.6

58.5

52.2

Exchange differences on translating foreign operations

 

 

 

 

Changes taken directly to equity

359.3

–61.2

448.4

–138.6

Reclassification to profit or loss

–7.6

Changes recognized in equity

359.3

–61.2

448.4

–146.2

 

476.4

–39.9

506.3

–93.0

Other comprehensive income

332.4

–18.7

162.2

–108.6

Comprehensive income

582.0

323.8

1,045.2

819.0

of which attributable to Merck KGaA shareholders

578.5

324.9

1,034.8

820.0

of which attributable to non-controlling interests

3.5

–1.1

10.4

–1.0

© Merck KGaA, Darmstadt, Germany, Last Update 2014/11/13